Background: Overexpression of the epidermal growth factor 2 HER2 in breast cancer
Introduction
The human epidermal growth factor receptor 2 (HER2), also known as c-erbB-2 and HER2/neu, promotes cell growth and tumor development. HER2 protein overexpression is observed in 25% to 30% of primary breast cancers and is associated with shorter survival. 1 Trastuzumab is a recombinant DNA-derived humanized monoclonal antibody that selectively binds to the progression when trastuzumab was added to chemotherapy (doxorubicin/cyclophosphamide or paclitaxel) ( Table 1) . More important, a 5-month longer median overall survival was observed with the drug combination.
Several clinical questions concerning the optimal use of trastuzumab remain unanswered. Unfortunately, not all will be answered by clinical trials, in part because of a relative paucity of patients available who can be entered onto clinical research studies. This review is intended to identify some of the salient areas of controversy or lack of knowledge regarding the clinical use of trastuzumab in patients with breast cancer and to present available data that might assist clinicians in developing a rational approach to optimal clinical care of patients with HER2-overexpressing breast cancer.
Testing
The test used for determining HER2 protein expression in the trial by Slamon and colleagues 4 is an immunohistochemical (IHC) "clinical trial assay" that is not commercially available. Several other IHC tests are commercially available, such as the HercepTest (Dako Corp, Carpinteria, Calif). These usually report test results as 0, 1+, 2+, or 3+, with 3+ representing positive, 2+ indeterminate, and 0 or 1+ negative for HER2 protein expression. IHC tests performed in laboratories with a low testing volume were recently shown to correlate poorly with results from large-volume reference laboratories, a factor of particular concern to patients being accrued onto adjuvant treatment studies (Table 2) . 5, 6 More recent follow-up suggests that correlations are now closer (E. Perez, MD, personal communication, September 2002).
Some laboratories now use quantitative image IHC analysis that provide reports of tumor HER2 protein overexpression as follows:
• Favorable (staining intensity in tumor cells <1. 7) • Unfavorable (staining intensity >2. 4) • Indeterminate (staining intensity between 1.7 and 2.3)
Trastuzumab therapy is considered for breast cancer patients with tumors that demonstrate 3+ overexpression or are in the "unfavorable" IHC category.
Fluorescence in situ hybridization (FISH) technology measures the extent of HER2 gene expression. The PathVysion (Vysis Inc, Downers Grove, Ill) HER2 DNA probe is considered positive when the ratio of HER2 to CEP 17 (chromosome enumeration probe) is ≥2.
7 FISH testing is probably the "gold standard" evaluation of HER2 activity and provides the best correlation with clinical response to trastuzumab, 8 
Cardiac Toxicity
Trastuzumab is generally well tolerated. Hypersensitivity reactions are usually restricted to the period during or immediately following the first injection. After recovery from such a reaction, some patients have been re-treated together with prophylactic premedication. Some of these patients tolerated re-treatment, but others had reactions again. 10 Hematologic toxicity is infrequent, but anemia and leukopenia may be observed in patients who receive both trastuzumab and chemotherapy. Diarrhea has also been reported. 10 Cardiac toxicity, however, is the side effect of greatest clinical concern with trastuzumab treatment.
Cardiac dysfunction was an unexpected finding in the phase II trials of trastuzumab, so the data on incidence and severity of this complication are based on retrospective evaluation. Table 3 summarizes the reported incidence of cardiac toxicity in early trials of patients with metastatic disease. 4 There was a 4% risk of cardiac dysfunction in patients treated with trastuzumab alone, which resolved in 50% of patients after treatment. The highest risk of cardiac dysfunction (27%) occurred when trastuzumab was given together with anthracycline plus cyclophosphamide, and it was noted in 13% of patients treated with trastuzumab plus paclitaxel. It is of note that cardiac dysfunction also occurred (8%) after treatment with anthracycline plus cyclophosphamide alone. The continued use of trastuzumab did not cause further deterioration of cardiac function in the majority of patients so managed; in nearly all cases, cardiac function improved after treatment with standard therapy. 11, 12 The pathogenesis of trastuzumab-associated cardiotoxicity is not clear, although it is known that HER2 plays a role in embryonic cardiogenesis, 13 and one clinical study reported myocardial uptake of radiolabeled trastuzumab in 7 of 20 patients treated with trastuzumab.
14 Six of these 7 patients developed cardiotoxicity, but none of the 13 with no cardiac uptake had the complication. The possibility that trastuzumab amplifies or has an additional cardiotoxic effect when administered after anthracycline therapy has also been postulated. 15 Trastuzumab-associated cardiac toxicity differs from anthracycline-associated cardiac toxicity in at least three ways. First, whereas the risk of anthracycline-induced cardiotoxicity increases with increasing cumulative dose, 16 there is no evidence that the same association holds true for trastuzumab treatment. Some patients have received trastuzumab for many years without developing cardiac events. Second, severe cardiac toxicity is associated less often with trastuzumab than with anthracyclines, and cardiac effects are at least partially reversible.
11,12
Most patients have improvement in functional class and ejection fractions after treatment of heart failure or stopping trastuzumab. Lastly, cardiac biopsies performed on 6 patients at the M. D. Anderson Cancer Center have revealed no morphologic changes similar to anthracycline-induced cardiomyopathy. 
-Incidence of Cardiac Dysfunction in a Randomized Comparative Clinical Study of Trastuzumab Plus Chemotherapy vs Chemotherapy Alone and in Pooled Studies of Trastuzumab Monotherapy
The two factors that are clearly associated with an increased risk of trastuzumab-associated cardiotoxicity are age over 60 years and concurrent treatment using trastuzumab plus an anthracycline. 17 Other factors suspected of predisposing toward trastuzumab cardiac toxicity include a prior anthracycline dose ≥400 mg/m 2 , prior chest wall irradiation, and preexisting cardiac dysfunction. Tachycardia may be an early indicator of trastuzumab-associated cardiotoxicity, and measurement of this parameter is included in guidelines used at the Memorial Sloan-Kettering Cancer Institute to direct a formal assessment of cardiac function (Table 4) . 11 The measurement of left ventricular ejection fraction (LVEF) by multigated acquisition (MUGA) scanning is noninvasive and is the most commonly used tool for clinical monitoring of the heart during trastuzumab therapy. However, the significance of a fall in LVEF if the patient in asymptomatic patients, however, is unknown. Echocardiography is an alternate noninvasive tool that can identify both systolic and diastolic dysfunction as well as valvular and pericardial disease. Clinical guidelines for monitoring cardiac function before and during treatment with trastuzumab as well as guidance on managing trastuzumab-associated heart failure are now available.
11
More prospective data on changes in LVEF during trastuzumab treatment are emerging from the adjuvant and neoadjuvant studies that are evaluating the benefits of incorporation of trastuzumab into adjuvant chemotherapy protocols (Figure) . To date, several thousand women have been entered onto these adjuvant trials. Participants in the adjuvant trials have both baseline and subsequent monitoring for cardiac events included as an integral part of the studies.
Preliminary reports from these adjuvant studies indicate that some patients have a reduced LVEF after standard-dose doxorubicin plus cyclophosphamide (AC) treatment. For example, 5% of 1,044 women who completed AC treatment in the intergroup NCIG N9831 study fit the study criteria for prohibition of starting trastuzumab (E. Perez, MD, personal communication, September 2002). Arm 3 of this study was temporarily suspended in 2002 because of concern about cardiac events, but this arm has subsequently been reopened for case accrual, suggesting that the incidence and severity of trastuzumab-related cardiac events in these adjuvant studies is small. Indeed, this study is to be expanded to include high-risk nodenegative patients.
Metastatic Breast Cancer

Schedule
The most commonly used schedule for trastuzumab is a "loading" intravenous dose of 4 mg/kg given as a 90-minute infusion and followed by a weekly "mainteDue to copyright restrictions, this table has been removed from this online article.
Please refer to the printed version found in Cancer Control Journal, V9, N6, to view this table. nance" dose of 2 mg/kg that can be given over 30 minutes if the initial dose was well tolerated. 10 Studies of higher loading and maintenance doses have not demonstrated increased activity, 3 but the mean half-life of trastuzumab increases and clearance decreases with increasing doses, and the half-life of trastuzumab in the serum is now estimated to be approximately 30 days. 18 Gelmon et al 19 have reported that a loading dose of 8 mg/kg followed by a maintenance dose of 6 mg/kg given every 3 weeks provides serum trastuzumab concentrations equivalent to those achieved by the "standard" weekly dosing regimen. This alternate dosing regimen will likely be shown to be as effective and is more convenient than the weekly dosing regimen. It is now being incorporated into some clinical trials, including adjuvant trials, and it seems a reasonable choice to be included in standard clinical practice.
Trastuzumab Monotherapy
Two large trials have evaluated the antitumor effectiveness of trastuzumab alone in patients with HER2 overexpressing metastatic tumors. The first was a "salvage" trial and included 222 patients with prior chemotherapy.
2 Nevertheless, trastuzumab monotherapy gave a response rate (complete [CR] and partial [PR]) of 15%, and responses lasted 9.1 months. A trial by Vogel et al 3 studied patients at an earlier stage and reported a response rate (CR and PR) of 26% and clinical benefit (CR, PR, and stable >6 months) occurring in 38% of patients treated, with a median duration of response of 18.8 months. This salutary response rate suggests that trastuzumab alone might be a reasonable choice for those patients with a relatively limited extent of metastatic disease (eg, having similar tumor spread characteristics as patients who might be considered for hormonal therapy). Such early treatment with trastuzumab monotherapy would not seem to abrogate the effectiveness of later treatment with trastuzumab plus chemotherapy. In a phase II study by Burris et al, 20 patients were treated initially with trastuzumab alone and obtained a 21% incidence of response. Subsequent treatment with paclitaxel plus carboplatin induced responses in 11 of 20 responses. This rate is consistent with reports of combined trastuzumab-chemotherapy treatment given as "firstline" therapy. 4 
Combination With Chemotherapy
The seminal report by Slamon et al 4 demonstrated the now well-known information that, in patients with HER2-overexpressing metastatic breast cancer, the addition of trastuzumab to chemotherapy increases response rates, prolongs the duration of remissions, and lengthens survival in comparison to treatment with chemotherapy alone (Table 1 ). Deserving reemphasis is the finding that the chemotherapy-trastuzumab combination was associated with a 5-month longer median survival even though 67% of patients randomized to receive chemotherapy alone initially subsequently received trastuzumab. This suggests that "early" use of trastuzumab, ie, given with the first line of chemotherapy in patients with metastatic disease, is optimal.
Trastuzumab adds to the clinical benefit of several other chemotherapeutic drugs besides the doxorubicin/cyclophosphamide doublet and paclitaxel therapies reported by Slamon and associates. Taxanes have been further studied (Table 5) , [21] [22] [23] and combinations of trastuzumab with vinorelbine produce response rates that are often over 60% (Table 6) . [24] [25] [26] Response rates are always highest in those patients who have IHC 3+ or FISH+ test results.
Other agents that have been successfully combined with trastuzumab include gemcitabine 27 and capecitabine. 28 Despite the known association of cardiac toxicity with anthracycline-containing regimens, studies are in progress using liposome-encapsulated doxorubicin 29 and epirubicin 30 (Table 7 ).
Of great current interest is the use of trastuzumab with platinum plus taxane combinations ( given every 3 weeks plus weekly trastuzumab vs paclitaxel plus carboplatin given every 3 weeks plus weekly trastuzumab. The combination arm was more toxic but provided more responses that were of significantly longer duration than the paclitaxel/trastuzumab-alone arm. These data support trials of this approach for adjuvant therapy in high-risk breast cancer patients.
Combination With Hormones
Many questions arise regarding optimal management of patients with tumors that are characterized as being both estrogen receptor (ER)-positive and HER2-positive. This combination of tumor characteristics has suggested that use of tamoxifen in such patients might be detrimental to survival, but this study contains many flaws. Many clinicians believe that the response of breast cancer patients to hormone therapy with tamoxifen is diluted in HER2-positive patients. Lipton et al 36 have described a shorter time to progression in patients with metastatic breast cancer treated with hormones who had elevated levels of circulating HER2 in comparison with those who did not. Ellis et al 37 evaluated responses to neoadjuvant tamoxifen or letrozole in postmenopausal patients with locally advanced HER1/2-positive tumors who were also ER-positive, and compared outcomes to patients who had ER-positive, HER1/2-negative tumors ( Table 9 ).
The numbers are small but suggest that an aromatase inhibitor might be capable of at least partially ameliorating primary tamoxifen resistance. Two important studies are now in progress that will assess whether trastuzumab can enhance responses to aromatase inhibitors in postmenopausal women with HER2-positive and ER-positive metastatic tumors. One is a phase II study that evaluates the combination of letrozole plus trastuzumab. Another is a phase III study that compares anastrozole alone to anastrozole plus trastuzumab. In the adjuvant therapy situation, it seems reasonable to recommend the appropriate adjuvant hormonal therapy based on the ER-positivity of the tumor for patients with clinically localized ER-positive and HER2-positive tumors and not modify the approach based on the HER2-positivity.
Duration of Therapy With Trastuzumab
When trastuzumab is prescribed for patients with HER2-positive metastatic breast cancer, either alone or in combination with cytotoxic chemotherapy, the drug is usually continued for as long as clinical benefit ensues, even if the cytotoxic therapy component of the intervention is discontinued because of toxicity or intolerance. Thus, in the absence of severe toxicity (eg, cardiac toxicity), the drug may be administered for long periods, sometimes several years. Questions arise, however, when the breast cancer progresses. Should trastuzumab be stopped or continued? Should an alternate hormone or cytotoxic agent be used -alone or with trastuzumab? Since trastuzumab is a growth inhibitor, should it be continued indefinitely akin to the policy of ensuring life-long androgen blockade in patients with metastatic prostate cancer even in the face of progressive metastatic disease? 38 A decision on continuing trastuzumab after progression from management with trastuzumab alone or if combined with a hormone is relatively easy. There is an excellent chance of clinical response occurring if a drug combination of proven effectiveness (eg, trastuzumab plus a taxane or vinorelbine or a taxane/carboplatin doublet) were prescribed, and such an approach will generally be indicated. What approach should be used, however, if a patient has responded to a combined trastuzumab-chemotherapy approach and has then progressed?
One relevant clinical study in progress randomizes treatments to patients who have progressed after trastuzumab plus a taxane between vinorelbine alone and vinorelbine plus trastuzumab. Until data from such important trials are at hand, we are forced to rely on the retrospective data collection on first and second-line use of trastuzumab reported by Mackey et al 39 recognizing the inherent limitations of nonprospective data. First-line trastuzumab monotherapy was associated with a response rate of 41%, and the combination of trastuzumab plus a taxane 38%. Second-line trastuzumab therapy provided similar objective response rates, ie, 38% with a combination with a taxane and 27% with a combination with vinorelbine (Table 10 ). The similarity of the reported outcomes between first-and secondline usage suggests that it is reasonable to consider a different trastuzumab/chemotherapy combination as second-line treatment after failure or progression from an initial trastuzumab-chemotherapy combination. There are no good data to help direct use of third or later lines of trastuzumab combined with chemotherapy, so clinical judgment needs to be used. If the disease progression is relatively slow and the patient is in good clinical condition, then trial of a third trastuzumab/ chemotherapy combination could be considered. However, if there was no response to prior trastuzumab/chemotherapy combinations and disease progression is rapid, then it is probably reasonable to discontinue trastuzumab. In situations where the central nervous system (CNS) is the sole site of progression and systemic metastasis is well controlled, there is logic to continuing the trastuzumab with or without other chemotherapy treatment while managing the CNS metastasis appropriately.
Trastuzumab in Adjuvant Therapy
The effectiveness of trastuzumab plus chemotherapy in patients with HER2-positive metastatic breast tumors, 4 particularly since survival was prolonged, has generated great interest in the adjuvant arena. The largest currently active trials are summarized in the Figure. Accrual to these studies has been rapid, with over 1,000 patients having been entered onto many of the studies. An important concern with these studies is, of course, cardiac toxicity, and only patients screened to exclude those with preexisting cardiac problems are entered. Concern was heightened when accrual to arm 3 of the Breast Intergroup Trial N9831 was interrupted in early 2002 because of an apparent excess of cardiac events in that arm of the study. The study protocol safety and monitoring board has since lifted the proscription on case entry, however, suggesting that cardiac events were either not severe or not occurring at high rates or both. In addition, accrual to this protocol will soon include high-risk node-negative patients. Initial reporting on cardiac toxicity from the studies (E. Perez, MD, personal communication, September 2002) indicates that some patients have experienced a minor decline in LVEF after standard-dose doxorubicin plus cyclophosphamide therapy. Overall, the rates of cardiac events from trastuzumab alone or trastuzumab plus chemotherapy in these adjuvant or neoadjuvant studies seem to be low.
Most adjuvant studies in the United States are studying a 1-year duration of trastuzumab treatment, although the HERA study includes an arm with 2 years of treatment. One can speculate if a longer duration of adjuvant therapy should be studied using the example of tamoxifen where a 5-year treatment duration is appreciably superior to 1 year of treatment. 40 Central Nervous System Metastases It is perhaps not surprising that breast cancer patients with HER2-overexpressing tumors are at high risk for developing CNS metastases -either parenchymal brain or meningeal metastases. In part, this may be due to the fact that treatment with trastuzumab is allowing patients with HER2 overexpressing metastatic disease to live longer than they previously did, thus allowing more chance for tumor growth in the "sanctuary" of the CNS to occur and become evident. The incidence of this complication seems sufficiently high that it may be reasonable to include imaging of the brain in the initial tumor staging assessment of a patient with metastatic HER2-overexpressing breast cancer even in the absence of CNS symptoms and signs.
Since CNS metastases often occur when the non-CNS component of metastases is under good control by a treatment program including trastuzumab, it seems reasonable to continue the systemic approach for these patients as the CNS metastases are treated essentially independently. Studies of prophylactic treatment to delay or prevent brain metastasis in HER2 overexpressors have not been reported.
Conclusions
Since there is now a more uniform realization that breast cancer patients will derive benefit from trastuzumab only if the tumor is found to overexpress HER2 either by a 3+ or "unfavorable" IHC result or by a positive FISH test performed by a high-volume laboratory, there should be better discrimination as to which patients should receive the drug. Benefits accrue when the drug is prescribed alone or with a variety of cytotoxic antitumor agents and possibly hormones. Trastuzumab-associated cardiac disease remains a concern but appears to be a different entity than anthracycline-induced cardiac disease and is often reversible. Issues regarding the length of time that trastuzumab is prescribed after progression of disease are still open.
Adjuvant trials of trastuzumab plus chemotherapy are well underway, with rather reassuring early reports that suggest a low incidence of significant cardiac events. Results from studies that combine trastuzumab with other novel biologic agents are awaited with interest.
